The program is still filling in: some talks have no title yet and more speakers will be added. We’ll add new sessions, the organizations presenting them and stand numbers once the floor plan is published.

Biosimilars, regulation and access at Festival of Biologics USA 2027

Apr 13–14, 2027 Boston, MA ~2k attendees Website

10 organizations at Festival of Biologics USA 2027 present work in biosimilars, regulation & access: 4 suppliers and service providers, 3 academic, government and non-profit bodies and 3 drug developers. Between them they bring 9 presentations to the program. Most represented: UC San Diego, Access to Medicine Foundation and American Oncology Network. As of Oct 15, 2026.

All 126 organizations at Festival of Biologics USA 2027 →

Showing 1–10 of 10 organizations

Organization	Festival of Biologics USA 2027 Attendance
UC San Diego San Diego, CA
	Talk Tue Apr 13 13:50 Bioprocessing to make biosimilars accessible Biosimilars Talk Tue Apr 13 16:40 Leveraging AI in Computational Medicine AI & Data
Access to Medicine Foundation Amsterdam, Netherlands
accesstomedicinefoundation.org Gov/NGO Non-profit that analyzes how pharmaceutical companies improve access to medicine in low- and middle-income countries.	Keynote Tue Apr 13 09:10 Making high impact decisions across the value chain to effect access and affordability Keynotes Biosimilars, regulation & access
American Oncology Network Fort Myers, FL
aoncology.com Consulting & services Network of community oncology practices, supplying them with practice management, pharmacy and value-based care services.	Talk Tue Apr 13 12:00 Revolutionizing Cancer Care: the impact of biosimilars on the Community Oncology Frontline Biosimilars
Complex Carbohydrate Research Center Athens, GA
	Talk Tue Apr 13 15:10 Analytical development and characterization of biosimilars Biosimilars
Ipca Laboratories Mumbai, India
ipca.com Large pharma Makes and markets finished formulations and active pharmaceutical ingredients, and develops biosimilars.	Talk Tue Apr 13 14:30 Ensuring High Biosimilarity Through Advanced Processes and Characterization Approaches Biosimilars
Kashiv Biosciences
kashivbiosciences.com Biotech Develops biosimilars and complex generic medicines; acquired by Amneal Pharmaceuticals in 2026.	Talk Tue Apr 13 16:40 Streamlined Development: 2-year perspective what's changed Why regulators now let biosimilars, near-copies of existing biologic drugs, skip comparative efficacy trials, shifting the focus to detailed lab comparisons.
MJH Life Sciences Cranbury, NJ
mjhlifesciences.com Consulting & services Healthcare media company publishing clinical news, journals and events for physicians, pharmacists and life science companies.	Talk Tue Apr 13 11:00 New Development of Biosimilars in US, including Immunotherapy agents for cancer, such as pembrolizumab Biosimilars
Orchard Therapeutics London, United Kingdom
orchard-tx.com Biotech Develops hematopoietic stem cell gene therapies for severe rare diseases; part of Kyowa Kirin.	Talk Tue Apr 13 11:40 Launching a biosimilar: the US landscape for biosimilar products Biosimilars
ProductLife Group Paris, France
plglifesciences.com Consulting & services Consultancy providing regulatory affairs, pharmacovigilance, quality, market access and engineering services across the product lifecycle.	Booth Exhibiting (no floor booth listed)
Weave Bio
weave.bio Software & AIGold sponsor AI platform for drafting and managing regulatory submissions and health authority questions, keeping dossiers linked to source data.	Booth Exhibiting (no floor booth listed)